Visit Website →
← Back to blog

Pharmacogenomics in EHRs: Map One Gene Drug Pair in FHIR First

October 14, 2026
Pharmacogenomics in EHRs: Map One Gene Drug Pair in FHIR First

The fastest, most maintainable path to clinically usable pharmacogenomics in the EHR maps lab outputs to FHIR-standard discrete resources, stores genotype, phenotype, and activity score alongside a linked PDF, uses a genomic indicator repository for visibility, and layers in tiered clinical decision support with living reanalysis governance. This approach favors interoperability and CDS readiness over proprietary shortcuts. Before building anything, identify one to three high-priority gene-drug pairs and confirm how your reference lab delivers results today.

TL;DR:

  • Store genotype, diplotype, phenotype, and activity score as queryable FHIR observations, with assay details and a linked PDF for clinician review and audit.
  • Check the active medication list before firing pharmacogenomic alerts, because enzyme inhibitors or inducers can make a patient’s effective phenotype differ from genotype predictions.
  • Reserve interruptive alerts for CPIC level A or B pairs; deliver lower evidence findings through passive guidance, then monitor override rates and adjust thresholds.
  • Pilot one or two priority pairs of genes and drugs in a single service line, with pharmacist review, before expanding the panel.
  • Assign a named owner to track guideline changes, rerun phenotype translations for affected patients, and notify clinicians before revised recommendations take effect.
SignalPGx
Bring PGx Reports Into EHR Workflows
SignalPGx creates physician-reviewed PGx reports and supports EHR integration through HL7 and FHIR standards for laboratory workflows.
Visit SignalPGx

Table of Contents

FHIR mapping and data model: the discrete fields and profiles to use

Wrap each pharmacogenomic report in a Genomic Report or DiagnosticReport resource, then use Observation resources to carry the genotype and diplotype strings your CDS engine will read. Medication-specific implications belong in the Therapeutic Implication and Medication Recommendation profiles defined by the HL7 Genomics Reporting Implementation Guide, which was built specifically to let EHRs and CDS engines interpret pharmacogenomic findings without custom parsing logic.

Your data model needs several elements to function clinically, not just archivally:

  • Genotype, diplotype, phenotype, and activity score, each as a discrete, queryable value
  • Assay metadata, specimen type, and collection or result date
  • A DocumentReference link to the original lab PDF for clinician review
  • Standard medication coding within each Therapeutic Implication, scoped to your jurisdiction's code system
  • One medication per Therapeutic Implication where the clinical logic allows it, which keeps downstream CDS rules simpler to maintain

Most reference labs still send results as PDFs. Building or procuring a pipeline that converts VCF or processed genotype output into FHIR-compliant resources, rather than depending on scanned documents, is what actually enables automated CDS. For a deeper walkthrough of DocumentReference patterns specifically, see our guidance on attaching lab reports via FHIR.

Pro Tip: Map one gene-drug pair end to end, from lab interface to Therapeutic Implication to CDS trigger, before scaling to a panel. It surfaces mapping gaps early, when they are cheap to fix.

Documenting results in the EHR: discrete storage and genomic repositories

Storing a PGx result as a static PDF locks that data out of your CDS engine entirely. Institutional reports from programs including Penn, Mayo, and eMERGE/PREDICT describe a pattern that avoids this: discrete lab observations for genotype, phenotype, and activity score, paired with a genomic indicator repository that drives alerts, plus the original PDF attached for audit.

Discrete PGx results linked to genomic repository and alert

A genomic indicator, or Gen-Ind, repository auto-documents phenotype from interfaced results and gives your team granular edit and view permissions. Compared with repurposing problem or allergy lists, a dedicated Gen-Ind repository is easier to maintain and update as guidelines change.

For external labs that only deliver PDFs, a two-step manual workflow keeps data usable:

  1. Pend a discrete entry for genotype and phenotype as soon as the PDF arrives.
  2. Route the pended entry to a pharmacist or genetics reviewer for verification against the source document.
  3. Finalize the entry, link it to the genomic indicator record, and let CDS pick it up from there.

Version your genotype-to-phenotype translation tables with a change log. When a phenotype gets reclassified under updated guidance, you need to trace exactly which patients are affected.

Pro Tip: Treat the translation table like source code: every change gets a version number, a reviewer, and a timestamp.

Designing clinical decision support: tiered alerts and phenoconversion

Reserve interruptive alerts for the drug-gene pairs with the strongest evidence, generally CPIC level A or B, and route everything else through passive inline banners or order-entry hints. This single design choice does more to prevent alert fatigue than any downstream tuning effort.

Build every alert against the five rights of CDS:

  • Right information: the specific genotype-guided recommendation, not a generic warning
  • Right person: the prescriber or pharmacist who can act on it
  • Right intervention: a dose change, alternative agent, or monitoring step
  • Right channel: inline guidance versus a hard stop
  • Right time: at the point of prescribing, not buried in a results tab

Phenoconversion complicates all of this. A patient's genotype-predicted phenotype can shift when a current medication inhibits or induces the relevant enzyme, so CDS logic needs to evaluate the active medication list before firing an alert, not rely on the static genetic result alone.

A published systematic review found pharmacogenomics is the most implemented precision medicine domain in CDS literature, yet few systems used standards-based approaches like FHIR, with most relying on proprietary or local builds. That gap is exactly where a standards-first design pays off over time.

Run simulated patient scenarios before go-live, then track override rates after launch and adjust thresholds based on what clinicians actually act on.

Implementation steps, governance, and workflow playbook for teams

Phase the work rather than attempting a full panel on day one:

  1. Select one or two initial gene-drug pairs with strong evidence and clear clinical impact.
  2. Build and validate translation tables against CPIC's genotype-to-phenotype resources.
  3. Test the lab interface, including how discrete results and PDFs arrive together.
  4. Pilot EHR display and CDS in one service line before expanding further.
  5. Scale to additional gene-drug pairs once the pilot workflow is stable.

Governance needs real ownership, not a committee in name only. Successful institutional rollouts rely on multidisciplinary teams spanning a pharmacy or clinical champion, a genetics lead, EHR analysts, the lab or LIS team, and privacy and compliance staff, with defined approval gates for any change to CDS language or phenotype classification.

Operationally, this means a documented lab interfacing schedule, a pended-review workflow for manual entries, and a notification process so clinicians learn when a stored result gets reclassified. Living reanalysis depends on this last piece: automated detection of guideline changes, a re-run of translation logic against affected patients, and a clinician notification and re-signoff step before updated recommendations go live.

Pro Tip: Assign one person, not a rotating group, to own the guideline-monitoring step. Shared ownership is how reanalysis quietly stops happening.

Practical lessons from implementation work

Automating genotype-to-phenotype translation inside the lab or LIS, rather than leaving it to manual EHR entry, removes a recurring source of transcription error and downstream delay. Piloting with a pharmacist-led sign-off workflow tends to build clinician trust faster than a purely automated rollout, since it keeps a qualified reviewer in the loop on every new result.

Teams weighing build versus buy should weigh time-to-pilot and the ongoing burden of reanalysis against internal engineering capacity. A platform offering FHIR-native integration, living reanalysis, and white-label reporting can compress a multi-month build into a matter of weeks for labs that need to move fast without standing up that infrastructure from scratch.

What actually determines success here

The technology choices in this playbook matter less than most teams assume. Standards adoption, discrete storage, and tiered CDS are necessary, but implementation science, meaning workflow design, clinician champions, and disciplined testing, determines whether any of it gets used. Programs that treat FHIR mapping as the finish line tend to stall at the clinician adoption stage.

The more common mistake is scope. Teams reach for a full gene panel on launch day instead of proving the workflow on one or two high-impact pairs first. A narrow, well-tested pilot earns clinician trust faster than a broad one that misfires on its first alert.

If there is one place to invest disproportionately, it is the reanalysis process. Guidelines change, and a phenotype that was accurate at reporting time can become outdated within a year. A program without a documented re-evaluation and notification process is building on a result that has an expiration date nobody is tracking.

— Tarek

How SignalPGx supports faster PGx reporting and EHR integration

We offer a platform designed for labs needing FHIR-based pharmacogenomic reporting to avoid a multi-year internal build. Our system handles:

  • White-label PGx reporting that your lab can brand and deploy through our PGx reporting infrastructure
  • Living reanalysis that updates recommendations automatically as guidelines evolve
  • HL7/FHIR integration designed to plug into existing EHR workflows
  • HIPAA and GDPR compliance built into the reporting pipeline

SignalPGx

When a pilot needs to launch in weeks rather than quarters, our Discovery & Strategy and Deployment & Integration services can scope your gene-drug priorities and get a working interface in front of clinicians fast.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

What FHIR resources should store pharmacogenomic results?

Use a Genomic Report or DiagnosticReport to wrap the overall result, Observation resources for genotype and phenotype values, and the Therapeutic Implication and Medication Recommendation profiles from the HL7 Genomics Reporting Implementation Guide for medication-specific guidance. This keeps data queryable by CDS engines instead of locked in a document.

Why store genotype data as discrete fields instead of PDFs?

Discrete genotype, phenotype, and activity score values let clinical decision support query and act on results automatically, while a PDF alone cannot trigger an alert. Institutional experience shows discrete storage paired with a linked PDF supports both clinician review and automated CDS.

What is phenoconversion and why does it matter for CDS?

Phenoconversion happens when a current medication changes a patient's effective drug-metabolizing phenotype away from what their genotype alone would predict. CDS logic needs to check the active medication list at the time of prescribing, not just the stored genetic result, to avoid firing an inaccurate alert.

How do we avoid alert fatigue with pharmacogenomic CDS?

Limit interruptive alerts to the highest-evidence, highest-risk gene-drug pairs and use passive inline guidance for everything else. Monitoring override rates after launch and adjusting thresholds based on real clinician behavior keeps the alert burden manageable over time.

How quickly can a lab deploy FHIR-based PGx reporting?

Build timelines vary by internal engineering capacity and the number of gene-drug pairs in scope. Vendor-supported white-label deployments, such as our PGx reporting platform, are designed to get a lab to a working pilot within days rather than months.

Sources